This is unpublished

H. Joachim
Deeg
M.D.

he, him, his
Physician & Research Faculty
Pinned
Academic
Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center
Miklos Kohary and Natalia Zimonyi Kohary Endowed Chair, Fred Hutch
Professor, Division of Medical Oncology, University of Washington
Sites of Practice
Seattle Cancer Care Alliance

Photo: Fred Hutch

Education, Training, Board Certifications

  • M.D., Friedrich Wilhelms Universität, Bonn, Germany 
  • Internship and Residency, University of Bonn
  • Internship and Residency, University of Rochester 
  • Fellowship, UW 
  • Medical Oncology, American Board of Internal Medicine 
  • Internal Medicine, American Board of Internal Medicine

Clinical Expertise 

  • Hematopoietic stem cell transplantation 
  • Aplastic anemia 
  • Myelodysplastic syndromes 
  • Myeloproliferative neoplasms
  • Graft-vs.-host disease 

Affiliations

Publications

 

Research and/or clinical interests 

Dr. Joachim Deeg is an expert in bone marrow failure and blood and bone marrow cancers. He is interested in how leukemia develops, especially via a precancerous blood disorder called myelodysplastic syndrome, or MDS. His research encompasses pathophysiology, genetics and gene regulation of this disorder and its progression to leukemia. He also leads clinical trials of new treatment approaches for MDS. He has established bone marrow transplantation from healthy donors as a curative therapy for MDS, aplastic anemia and a group of blood cancers called myeloproliferative neoplasms. Dr. Deeg has also worked extensively in animal models and developed a regimen, adopted worldwide, for the prevention of graft-vs.-host disease, or GVHD, a common and potentially dangerous complication of blood stem cell transplantation. His recent studies have included the use of alpha-1 anti-trypsin to treat GVHD. Dr. Deeg is also interested in the ethics of decision-making regarding the optimal treatment strategy for a given patient.